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The last decade has witnessed an evolution of our understanding of the biology of the
metastatic cascade. Recent insights into the metastatic process show that it is complex,
dynamic, andmulti-directional.This process starts at a very early stage in the natural history
of solid tumor growth leading to early development of metastases that grow in parallel with
the primary tumor.The role of stem cells in perpetuating cancer metastases is increasingly
becoming more evident. At the same time, there is a growing recognition of the crucial
role circulating tumor cells (CTCs) play in the development of metastases. These insights
have laid the biological foundations for therapeutic targeting of CTCs, a promising area of
research that aims to reduce cancermorbidity andmortality by preventing the development
of metastases at a very early stage. The hematogenous transport phase of the metastatic
cascade provides critical access to CTCs for therapeutic targeting aiming to interrupt the
metastatic process. Recent advances in the ﬁelds of nanotechnology andmicroﬂuidics have
led to the development of several devices for in vivo targeting of CTC during transit in the
circulation. Selectin-coated tubes that target cell adhesion molecules, immuno-magnetic
separators, and in vivo photo-acoustic ﬂow cytometers are currently being developed for
this purpose. On the pharmacological front, several pharmacological and immunological
agents targeting cancer stem cells are currently being developed. Such agents may ulti-
mately prove to be effective against circulating tumor stem cells (CTSCs). Although still in
its infancy, therapeutic targeting of CTCs and CTSCs offers an unprecedented opportunity
to prevent the development of metastasis and potentially alter the natural history of cancer.
By rendering cancer a “local” disease, these approaches could lead to major reductions in
metastasis-related morbidity and mortality.
Keywords: circulating tumor cells, cancer stem cell, epithelial–mesenchymal transition, immuno-magnetic
separation, selectin ligands, targeted therapy, metastasis
THE BIOLOGY OF THE METASTATIC CASCADE
The metastatic spread of cancer is the main cause of morbidity
and mortality in cancer patients (Duffy et al., 2008). The devel-
opment of metastases from solid tumors is a complex multi-step
process and is one of the most enigmatic aspects of cancer biology.
Recently, studies using in vivo vital microscopy have shed more
light on the physiology of the metastasis. These studies show a
metastatic process that proceeds in a pre-determined cascade com-
prising the following steps: neoangiogenesis, trans-endothelial
migration, entry into the blood stream (intravasation), transport
through the vasculature followed by extravasation, and ultimately
resulting in colonization and growth at distant sites (Chambers
et al., 1995; Morris et al., 1997; Figure 1).
Although the biology of the metastatic process is not fully
understood, new insights are emerging from recently discovered
metastatic phenomena. For instance, it was previously believed
that the development of metastases is a late event that occurs
only after primary tumors reach a certain critical mass (the
linear-progression model). Recent evidence indicates that tumor
cells disseminate at a relatively early stage of the natural history
of tumor growth. This leads to parallel growth of metasta-
sis along with primary tumor growth (the parallel-progression
model; Klein, 2009). Similarly, metastatic spread has been clas-
sically viewed as a unidirectional process with dissemination of
cancer cells occurring only from primary tumors to form sec-
ondary metastases. On the contrary, recent experimental evidence
points toward a new paradigm where cancer progress is a multi-
directional process in which tumor cells are capable of self-seeding
the primary tumor (Kim et al., 2009; Comen et al., 2011).
The metastatic process is selective and inefﬁcient with many
cancer cells initially gaining access to the circulation but only a
few ultimately succeeding in proliferating as distant metastases
(Wong et al., 2001). In fact, it is estimated that only 1% of micro-
metastases eventually thrive as macro-metastases (Wittekind and
Neid, 2005). Despite this relative metastatic inefﬁciency, the
absolute magnitude of metastatic spread is enormous and rep-
resents the primary cause of cancer morbidity and mortality
(Wittekind and Neid, 2005; Chaffer and Weinberg, 2011).
THERAPEUTIC TARGETING OF THE METASTATIC CASCADE
Despite the tremendous toll of metastases on human mortality
and morbidity, the development of preventive anti-metastatic
therapies has been slow and often hampered by the lack of
understanding of the biology of the metastatic cascade (Mina and
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FIGURE 1 |The invasion–metastasis cascade.Tumor cells exit their
primary sites of growth (local invasion, intravasation), translocate systemically
(survival in the circulation, arrest at a distant organ site, extravasation), and
adapt to survive in distant tissues (micro-metastasis formation,
metastatic colonization). Adapted with permission from Valastyan and
Weinberg (2011).
Sledge, 2011). Most currently developed anti-metastatic therapy
strategies target the ﬁnal steps of the metastatic cascade such as
extravasated dormant cancer cells in the metastatic niche thus
missing the opportunity to interrupt metastases development at
earlier stages (Chambers et al., 2000; MacDonald et al., 2002).
Targeting earlier “up-stream” events in the metastatic cascade is
likely to be more effective in preventing metastases from devel-
oping with greater yield in reducing or even eliminating their
devastating clinical impact. The hematogenous transport phase
of cancer cells presents a particularly attractive opportunity for
therapeutic targeting for multiple reasons; ﬁrst, it occurs early
enough to provide a rational up-stream target for strategies aim-
ing to reduce or completely prevent the development of distant
metastases. Secondly, hematogenous transport represents the ﬁnal
common pathway of metastatic spread, even for tumors initially
spreading through lymphaticswhich eventually inter-connectwith
the circulatory system (Sleeman et al., 2011). Finally, the transport
phase is relatively accessible to a variety of pharmacological and
mechanical targeting interventions.
CIRCULATING TUMOR CELLS AS THERAPEUTIC TARGETS
Circulating tumor cells (CTCs) are cancer cells that detach from
the primary tumor and enter the bloodstream. Several systems
have been developed for isolation and characterization of CTCs
from blood samples including the FDA approved CellSearch
platform (Hughes and King, 2012; Yu et al., 2011). Using these
platforms,CTCs have been isolated fromblood samples of patients
with a variety of tumors including head and neck (Nichols et al.,
2011), breast (Swaby and Cristofanilli, 2011), lung (O’Flaherty
et al., 2011), colorectal, gastric, pancreatic (Takeuchi and Kita-
gawa, 2010), renal cell, urinary bladder, and prostate cancers
(Kruck et al., 2011). Recent studies show signiﬁcant correlation
between higherCTC counts and shorter overall survival in patients
withmetastatic breast, lung, andprostate carcinomas (Cristofanilli
et al., 2004; Miller et al., 2010). These studies support a critical role
for CTCs in tumor progression and metastases. As a result, it is
now hypothesized that targeting CTCs during their hematogenous
transport could lead to effective interruption of the metastatic cas-
cade and ultimately, reduction of cancer morbidity and mortality
(Faltas, 2010).
CIRCULATING TUMOR STEM CELLS AND
EPITHELIAL–MESENCHYMAL TRANSITION
Circulating tumor cells occur in heterogeneous populations
with pronounced differences in their metastatic potential. Some
CTC populations undergo a transformative process called
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epithelial–mesenchymal transition (EMT) that leads to acquisi-
tion of enhanced migratory and invasive properties (Bonnomet
et al., 2010). Cells undergoing EMT also acquire cancer stem
cell (CSC)-like characteristics including the capacity for self-
renewal, re-differentiation, dormancy, active DNA repair, drug
resistance, and resistance to apoptosis leading to resistance to
chemotherapeutic agents (Monteiro and Fodde, 2010; Chaffer and
Weinberg, 2011). These CTCs possessing stem cell like character-
istics will be referred to in this review as circulating tumor stem
cells (CTSCs). Because of these unique characteristics, CTSCs
are considered high-value targets for anti-metastatic therapies.
Unfortunately, the biology of this unique subset of cells is not
fully understood, posing a challenge to precise identiﬁcation
of cell populations most likely to initiate metastases in distant
organs or those that are most difﬁcult to eliminate using exist-
ing chemotherapeutic approaches (Faltas et al., 2011). Several
markers have been proposed to identify CTSCs including CD133,
a glycoprotein expressed on hematopoietic progenitors. In one
study, real-time reverse-transcriptase polymerase chain reaction
was used to detect mRNA of CD133 as a marker for CTSCs
in patients with colorectal cancer. This study demonstrated the
prognostic signiﬁcance of a combined carcinoembryonic antigen
(CEA)/cytokeratin (CK)/CD133 pattern but not for CD133 alone
in patients with Dukes’ B and C colorectal carcinoma (Iinuma
et al., 2011). A marker “proﬁle” that combines markers pre-
dicting poor clinical outcomes, resistance to chemotherapy, or
susceptibility to apoptosis evasion (CD26, epidermal growth fac-
tor receptor, myeloid leukemia cell differentiation protein Mcl-1,
and Ki-67) with the stem cell marker CD133 is currently under
investigation. This approach is expected to result in improved
ability to detect and target genuinely metastatic CTSC phenotypes
(Faltas et al., 2011).
APPROACHES FOR THERAPEUTIC TARGETING OF
CIRCULATING TUMOR CELLS AND CIRCULATING
TUMOR STEM CELLS
Improved understanding of metastatic biology has laid the bio-
logical foundations for therapeutic targeting of CTCs and CTSCs.
Table 1 summarizes important concepts in metastatic biology and
their implications for therapeutic targeting. In vivo therapeutic
targeting of CTCs and CTSCs to interrupt the transport phase of
the metastatic cascade and subsequent development of metastasis
is in itself, a novel concept (Hughes and King, 2012) and variety
of targeting approaches are currently under development.
Table 1 | Emerging concepts in metastatic biology and their implications for therapeutic targeting.
Biological concept Implications for therapeutic targeting Reference
• Metastasis progresses in a sequence of events.
• Each step in the metastatic cascade is considered
rate-limiting.
Interrupting the hematogenous transport step can potentially
interrupt the entire cascade.
Chambers et al. (1995),
Morris et al. (1997)
•The parallel-progression model of metastatic tumors. Early targeting of CTC can eliminate early development of
micro-metastases. Anti-metastatic therapies may need to be
eliminated in conjunction with therapy for primary tumors.
Klein (2009)
• Self-seeding of primary tumor. Therapeutic targeting of CTC even after the development of
secondary metastases may still alter the natural history
of the disease.
Kim et al. (2009),
Comen et al. (2011)
• Hematogenous transport represents the ﬁnal
common pathway of metastatic spread.
Hematogenous transport is a rational therapeutic target to
prevent the development of metastases.
Sleeman et al. (2011)
• Hematogenous spread is an early event in the
metastatic cascade.
The hematogenous transport phase provides a unique
therapeutic window for targeting an “up-stream” event in the
metastatic cascade.
Faltas (2010)
• Circulating tumor cells (CTCs) predict survival of
patients with metastatic cancers.
Targeting circulating tumor cells could potentially prolong
survival of cancer patients.
Cristofanilli et al. (2004),
Miller et al. (2010)
• Circulating tumor stem cells (CTSCs) capacity for
self-renewal, re-differentiation, dormancy, active DNA
repair, drug resistance, and resistance to apoptosis.
CTSCs are considered high-value targets for anti-metastatic
therapies. Better proﬁling of CTSCs could have profound
implications for therapeutic targeting.
Faltas et al. (2011)
• CTCs can undergo a transformative process called
epithelial–mesenchymal transition (EMT) that leads
to the acquisition of enhanced migratory and
invasive properties.
Cell signaling pathways affecting regulation of EMT are
attractive therapeutic targets for anti-metastatic therapies.
On the other hand EMT can alter surface marker expression
leading to decreased efﬁcacy of anti-metastatic therapies
targeting speciﬁc epithelial surface markers.
Aalaoui-Jamali et al. (2011)
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PHARMACOLOGICAL AND IMMUNOLOGICAL TARGETING APPROACHES
Pharmacological targeting depends primarily on the identiﬁca-
tion of suitable molecular targets which are over-expressed and
critically important for CTCs’ survival and function. CTSC sub-
sets are high-value targets because of their aggressive invasive
and proliferative characteristics and their resistance to traditional
chemotherapeutic agents. Current therapeutic approaches focus-
ing on targeting CSCs in primary tumors could be extended to
target CTSCs that express the same therapeutic targets.
Targeting surface receptors expressed preferentially in CSCs is
one promising approach that could potentially be extended to
CTSCs. In a study of human breast cancer xenografts in Swiss nude
mice, an antibody targeting CD44, a surface marker expressed on
CSCs, was found to reduce tumor growth and to prevent relapse
after chemotherapy (Marangoni et al., 2009). In another study,
targeting CD44 with short interfering RNA (siRNA) resulted in
suppression of human colon cancer xenografts (Subramaniam
et al., 2007). Investigators have also developed a fusion protein
(dCD133KDEL) targeting CD 133, another CSC marker expressed
by several human cancer cells (LaBarge and Bissell, 2008; Wang
et al., 2008; Faltas et al., 2011). The fusion protein resulted in sig-
niﬁcant tumor reduction in a xenotransplant model of CD133+
human head and neck cancer (Waldron et al., 2011).
Epithelial cell adhesion molecule (EpCAM) is another interest-
ing therapeutic target (Armstrong and Eck, 2003). It is frequently
expressed on CSCs from breast, colon, pancreas, and prostate
tumors (Gires et al., 2009). EpCAM is also expressed on CTCs
but not on blood cells. This preferential expression is the basis
of many diagnostic assays used to isolate CTCs from the blood-
stream (Liljefors et al., 2005; Yu et al., 2011). Clinical trials using
anti-EpCAM monoclonal antibodies slowed progression and pro-
longed survival in patient with metastatic colorectal carcinoma
(Liljefors et al., 2005).
As mentioned earlier; CTSCs can arise through the EMT pro-
cess (Bonnomet et al., 2010). Hence, signaling pathways affecting
the regulation of EMT are attractive therapeutic targets for anti-
metastatic therapies. Inhibitors of PAR6A, Notch1, Hedgehog,
Wnt, integrins, polycomb repressive complex 1 (PRC1) protein,
Bmi-1, claudin, tyrosine kinase, and Rho GTPases have been
reported to block EMT and a few select agents are undergoing
early clinical trials (Aalaoui-Jamali et al., 2011).
In the future, a better understanding and proﬁling of shared
characteristics betweenCTCs,CTSCs, andCSCs indifferent tumor
subtypes will allow extension of the CSC targeting approaches
mentioned above toward the design of speciﬁc anti-CTSC ther-
apies. More clinical trials need to be designed to assess the
impact of targeted pharmacological approaches against CTCs and
CTSCs that aim to reduce metastases. These trials should include
biomarker endpoints such CTC and CTSC counts and character-
istics as well as survival endpoints to assess the full clinical impact
of hindering metastasis development and to guide further drug
development.
IN VIVO DEVICE-BASED TARGETING APPROACHES
Devices designed to target CTCs and CTSCs in vivo can be
either intra-corporeal or extra-corporeal. Intra-corporeal devices
such as indwelling vascular devices (Faltas, 2010) and shunts
(Wojciechowski et al., 2008) have the potential to continuously
screen the entire circulation for CTC and CTSCs. This could theo-
retically improve the absolutemagnitude of capture andultimately
result in greater improvements in clinical outcomes. On the other
hand, intra-corporeal devices are susceptible to infection, clot-
ting, and other physiological and anatomical design limitations
(Faltas, 2010). Alternatively, extra-corporeal devices could isolate
and destroy cancerous cells before returning the purged blood to
the systemic circulation. Such design avoids many of the limita-
tions inherent to intra-corporeal devices achieving higher capture
efﬁciency per pass. However, the potential increase in capture efﬁ-
ciency per pass may be offset by limited contact time between the
device and the circulationbecause extra-corporeal devices canonly
be used intermittently leaving periods of unopposed CTC dissem-
ination. Some of these devices could also function as “theranostic”
devices that simultaneouslymonitor CTC counts and analyze their
biological characteristics while purging the circulation fromCTCs.
The resulting data could have prognostic as well as, predictive
implications.
Circulating tumor cells and CTSCs can be isolated by tar-
geting cell adhesion molecules expressed on their surfaces. One
approach utilizes a vascular shunt functionalized with E-selectin
to induce CTCs to adhere to and roll over the shunt’s internal
surface functionalized with immobilized TNF-related apoptosis-
inducing ligand (TRAIL) molecules. This device resulted in
apoptosis of 30% of CTCs after 1 h of rolling exposure (Rana
et al., 2009). In another study, a P-selectin based vascular shunt
functionalized with nanoscale liposomes containing siRNA was
successful in delivering siRNA into leukemic cells inducing inhi-
bition of target gene expression (Huang and King, 2009). The
same approach can be extended to deliver siRNA into CTCs
(Hughes and King, 2012).
Immuno-magnetic separation is another promising strategy
that utilizes magnetic nano or micro-particles tagged with anti-
bodies targeting surface receptors expressed by CTC/CTSC pop-
ulations of interest followed by application of a magnetic ﬁeld
to capture cell-magnetic particle complexes. This principle is uti-
lized by the CellSearch diagnostic device approved for ex vivo
separation of EpCAM+ CTCs in peripheral blood samples. The
same concept is currently under development for in vivo appli-
cations. In one study aiming to prevent direct metastatic spread
of ovarian cancer inside the peritoneal cavity, researchers used
super-paramagnetic nanoparticles conjugated to a peptide target-
ing the EphA2 receptor expressed by ovarian cancer cells. The
application of an external magnetic ﬁeld resulted in cell cap-
ture from a ﬂow stream in vitro and from the peritoneal cavity
of experimental mice in vivo (Scarberry et al., 2008, 2010). In
another study mice receiving this treatment were found to have
tumor progression 10.77-times slower than that in the control
group (Scarberry et al.,2011). The investigators envision the exten-
sion of this concept to produce a “dialysis-like” treatment that
removes malignant cells from the body. This could potentially
result in improved long-term survival of ovarian cancer patients
(Scarberry et al., 2008).
On a parallel front, an extra-corporeal microﬂuidic immuno-
magnetic blood-cleansing device has been developed to treat sep-
sis. The device uses magnetic micro-beads coated with polyclonal
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antibodies to bindCandida albicans in the blood. Bead–fungi com-
plexes were then subjected to a continuous magnetic gradient that
enabled uninterrupted high throughput separation of fungi from
whole blood. A multiplexed version of the device achieved over
80% clearance of fungi from contaminated blood at a ﬂow rate of
20 ml/h in a single pass. The same technology can also be adapted
to purge the blood from CTCs (Lee, 2009; Yung et al., 2009).
In vivo photo-acoustic ﬂow cytometry is another emerging
CTC separation technology. In one variant,melanin nanoparticles
that naturally occur in melanoma CTCs were exposed to photons
from a laser. The nanoparticles absorbed the photons generating
heat energy that lysed CTCs while simultaneously expanding to
produce acoustic waves detectable by an ultrasound transducer
(Weight et al., 2006; Hughes and King, 2012). The same tech-
nique was applied to capture breast cancer CTCs using magnetic
nanoparticles functionalized to target urokinase plasminogen acti-
vator, a receptor commonly expressed on breast CTCs. This was
followed by photo-acoustic detection using gold-plated carbon
nanotubes conjugated with folic acid as a second contrast agent
(Galanzha et al., 2009a). In another study, photo-acoustic detec-
tionwas used to target CD44+CTSCs in amousemodel of human
breast cancer (Galanzha et al., 2009b).
CHALLENGES FACING THERAPEUTIC TARGETING
OF CTC AND CTSCs
Several challenges currently face CTC/CTSC therapeutic targeting
efforts. CTCs are rare in the general circulation relative to other
blood elements thus requiring ultra-efﬁcient targeting. Pharma-
cological agents designed to target CTC/CTSCs need to achieve
high selectivity while maintaining acceptable clinical toxicity, an
important and sometimes an elusive goal. Furthermore, incom-
plete characterization and proﬁling of CTC populations hinders
efforts to selectively target CTC subsets that are most likely to
develop into metastases. CTSCs are emerging as a potentially
high-value CTC subset but are still poorly deﬁned and incom-
pletely proﬁled to date (Faltas et al., 2011). Whereas a number
of pharmacologic agents that target CSCs are under development
(Aalaoui-Jamali et al., 2011), little is known regarding their speciﬁc
effectiveness against CTSCs.
Device-based approaches face unique challenges of their own.
While pre-clinical models have demonstrated proof of concept,
many technical and biocompatibility issues need to be resolved
before these devices reach clinical trials in humans. Such devices
need to reach a certain threshold of capture efﬁciency while main-
taining physiologic blood ﬂow to prevent thrombosis or tumor
seeding of the device (Faltas, 2010). Thromboembolic complica-
tions are to be anticipated with the use of such devices and while
these complications can be prevented or managed with concomi-
tant use of anticoagulants, this introduces signiﬁcant bleeding
risks that may decrease the overall clinical beneﬁt. Bloodstream
infection related to indwelling vascular devices is another seri-
ous clinical problem that could potentially complicate clinical
adoption of such technology. Approaches utilizing functionalized
surfaces face challenges related to bio-fouling by plasma pro-
teins and blood elements that alter the biological activity of such
functionalized surfaces (Hughes and King, 2012). Systems utiliz-
ing magnetic nanoparticles will require more robust data on the
potential long-term toxicity of these particles when used in vivo
(Scheinberg et al., 2010). Using animal-derived antibodies to iso-
late CTCs in humans could potentially induce hypersensitivity
reactions andwhile humanized antibodies can be synthesized, they
are generally more expensive.
CONCLUSION
Recent insights into the biology of the metastasis have improved
our understanding of the metastatic cascade and potential thera-
peutic targets. These insights have laid the biological foundations
for therapeutic targeting of CTCs, a promising area of research
that aims to reduce cancer morbidity and mortality by preventing
the development of metastases at a very early stage. Studies reveal
a multi-step metastatic process that is complex, dynamic, and
multi-directional. Metastatic cancer cells disseminate very early in
the course of solid tumor growth forming metastases that grow
in parallel with the primary tumor. The crucial role of CTCs and
CTSCs in initiating and perpetuating metastases is increasingly
being recognized. Despite challenges facing precise identiﬁcation
of CTSCs, they are likely to emerge as attractive therapeutic targets
because of their stem cell like properties. Several pharmacological
and immunological CSC targeting agents are being developed that
may eventually prove effective against CTSCs sharing the same
biological characteristics.
The hematogenous transport phase of the metastatic cas-
cade provides critical access to CTCs and CTSCs that permits
therapeutic targeting. Recent advances in the ﬁelds of nan-
otechnology and microﬂuidics have led to the development of
several devices for in vivo targeting of CTC during transit in
the circulation. Selectin-coated tubes that target cell adhesion
molecules, immuno-magnetic separators, and in vivo photo-
acoustic ﬂow cytometers are currently being developed for this
purpose. While pre-clinical models are showing promising pre-
liminary results, several technical and biocompatibility issues need
to be resolved before these devices could reach clinical trials
on humans.
Although still in its infancy, therapeutic targeting of CTCs and
CTSCs offers an unprecedented opportunity to prevent the devel-
opment of metastasis and potentially alter the natural history of
cancer. More research is needed to expedite the translation of these
promising technologies to clinical therapies. By rendering cancer
a “local” disease, these approaches could lead to major reductions
in metastasis-related morbidity and mortality.
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